Aloe-derived nanovesicles attenuate inflammation and enhance tight junction proteins for acute colitis treatment

Biomater Sci. 2023 Aug 8;11(16):5490-5501. doi: 10.1039/d3bm00591g.

Abstract

Inflammatory bowel disease (IBD) is a chronic recurrent inflammatory disease of the digestive tract that causes pain and weight loss and also increases the risk of colon cancer. Inspired by the benefits of plant-derived nanovesicles and aloe, we herein report aloe-derived nanovesicles, including aloe vera-derived nanovesicles (VNVs), aloe arborescens-derived nanovesicles (ANVs), and aloe saponaria-derived nanovesicles (SNVs) and evaluate their therapeutic potential and molecular mechanisms in a dextran sulfate sodium (DSS)-induced acute experimental colitis mouse model. Aloe-derived nanovesicles not only facilitate markedly reduced DSS-induced acute colonic inflammation, but also enable the restoration of tight junction (TJ) and adherent junction (AJ) proteins to prevent gut permeability in DSS-induced acute colonic injury. These therapeutic effects are ascribed to the anti-inflammatory and anti-oxidant effects of aloe-derived nanovesicles. Therefore, aloe-derived nanovesicles are a safe treatment option for IBD.

MeSH terms

  • Aloe* / metabolism
  • Animals
  • Colitis* / chemically induced
  • Colitis* / drug therapy
  • Dextran Sulfate
  • Disease Models, Animal
  • Inflammation / drug therapy
  • Inflammatory Bowel Diseases* / chemically induced
  • Inflammatory Bowel Diseases* / drug therapy
  • Mice
  • Mice, Inbred C57BL
  • Tight Junction Proteins / metabolism

Substances

  • Tight Junction Proteins
  • Dextran Sulfate